BCD-281 versus ocrelizumab for relapsing-remitting multiple sclerosis

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This phase 3, randomized, double-blind trial enrolls adults 18–55 with relapsing‑remitting MS (EDSS 0–5.5) and compares BCD‑281 to the reference drug ocrelizumab. Participants are randomized 1:1 and followed through a 72‑week double‑blind period, a 24‑week open‑label extension (weeks 72–96), and a 4‑week follow-up (weeks 96–100). The study measures clinical efficacy, safety, pharmacokinetics, pharmacodynamics, and immunogenicity, with required discontinuation of prior disease‑modifying therapies before dosing. The trial is sponsored by Biocad and conducted at LLC "Medis" in Nizhny Novgorod, Russia.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Provided written ICF to participate in the study.
* Male and female subjects aged 18 to 55 years inclusive at the time of signing the ICF.
* Diagnosis of multiple sclerosis, established in accordance with the McDonald criteria for the diagnosis of multiple sclerosis (2017 revision).
* Relapsing-remitting multiple sclerosis.
* The total EDSS score 0-5.5 inclusive.
* Documentary evidence of the following at the time of signing the ICF:

  1. at least one relapse within the last12 months, and/or
  2. 2 relapses within the last 24 months, and/or
  3. at least 1 T1 Gd+ lesion detected on brain MRI and 1 relapse within 24 months prior to signing the ICF.
* Presence of IgG antibodies to the Varicella-Zoster virus.
* Neurological stability for 30 days prior to signing the ICF.
* Subject's willingness to discontinue previously prescribed DMTs from the day of the first administration of the IP and throughout the study.
* The ability of the subject to follow the Protocol procedures, according to the Investigator.
* Willingness of subjects of both sexes and their sexual partners of childbearing potential to use reliable methods of contraception from the time of signing ICF, throughout the study and for 5 months after the last dose of the drug in this study.

Exclusion Criteria:

* Primary progressive or secondary progressive MS.
* MS duration of more than 10 years with EDSS score of ≤2.0 at screening.
* Malignant form of MS.
* Other medical conditions that can affect the assessment of clinical picture of the MS.
* Inability to obtain high-quality MRI images and/or the presence of contraindications to MRI and the administration of gadolinium-containing contrast agents.
* Any comorbidities requiring treatment with systemic glucocorticoids and/or immunosuppressive drugs for the duration of the study, with the exception of MS.
* History of progressive multifocal leukoencephalopathy.
* Any acute or exacerbated chronic infections detected during screening that may have a negative impact on subject's safety during the study therapy.
* Concomitant diseases and/or conditions that may affect the assessment of the clinical picture of the underlying disease and/or significantly increase the risk of AEs during the study.
* Known alcohol or drug addiction, or current signs of alcohol/drug addiction.
* History of severe depression and/or a Beck Depression Inventory score of ≥16 at screening examination.
* History of a malignant disease within 5 years prior to screening.
* A diagnosis of HIV infection, hepatitis B or C .
* Inability to provide the subject with venous access.
* Pregnancy or breastfeeding, pregnancy planning and oocyte donation throughout the study and for 5 months after the last dose of ocrelizumab.
* A history of severe allergic or anaphylactic reactions to humanized and/or murine monoclonal antibodies.
* A history of using any prohibited medications or treatments defined in the study protocol.
* Abnormal laboratory blood values, as specified in the study protocol.

Where it's running

• LLC "Medis"
  Nizhny Novgorod, Russia Recruiting

Study contacts

• Study coordinator: Marina Krasnova
• Email: krasnovam@biocad.ru
• Phone: +7 (812) 380 49 33

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Rocbrutinib in PRL-Positive Relapsing-Remitting MS

  This study tests whether Rocbrutinib can help people with relapsing-remitting MS who have paramagnetic rim lesions, compared to dimethyl fumarate.

  Recruiting Phase 2 Guangzhou Lupeng Pharmaceutical Company LTD. · Beijing, Beijing Municipality · NCT07776743

• Indole-3-propionic acid supplementation for relapsing-remitting MS

  This trial tests whether taking oral indole-3-propionic acid (a gut-derived supplement) can help protect people with relapsing‑remitting MS from disease activity, nerve damage, and related metabolic problems.

  Recruiting Glostrup University Hospital, Copenhagen · Glostrup Municipality · NCT07318129

• Anti-CD20 maintenance vs. de-escalation in relapsing-remitting MS

  This trial tests whether continuing anti-CD20 therapy at standard maintenance is as good as a de-escalated approach in people with relapsing-remitting MS who have been on anti-CD20 treatment for at least 3 years.

  Recruiting Phase 3 University Hospital, Montpellier · Montpellier · NCT07189325

• Using eye movement biomarkers to track disease changes in active RRMS patients

  This study is testing if tracking eye movements can help doctors see how well a new treatment works for people with active Relapsing Remitting Multiple Sclerosis.

  Recruiting at 14 sites Phase 4 Novartis · Calgary, Alberta and 13 other locations · NCT06733922

• Imaging axonal damage and repair in multiple sclerosis

  This study is testing new MRI techniques to see how axons are damaged and repaired in people with multiple sclerosis over two years.

  Recruiting University Hospital, Basel, Switzerland · Basel · NCT05177523

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.